SELECTION OF THE OPTIMAL ANTIHYPERTENSION TREATMENT IN PATIENTS WITH CHRONIC HEART FAILURE WITH THE SIGNS OF CHRONIC KIDNEY DISEASE
https://doi.org/10.15829/1728-8800-2016-6-19-23
Abstract
Aim. To evaluate the effectiveness of fixed combination of perindopril arginine and amlodipine besilate (Prestans®, Les Laboratoires Servier) in optimal treatment scheme selection of arterial hypertension (AH) in patients with chronic heart failure (CHF) having the signs of chronic kidney disease (CKD).
Material and methods. Totally, 118 patients studied, with essential AH, with CHF. In 53 (44,9%) of those, thre were signs of CKD. The latter presented with a decreased glomerular filtration rate (GFR) and increased cystatin C in the blood plasma (1,4+0,3 mg/L). As the treatment, they were prescribed the fixed combination of perindopril arginine and amlodipine besilate—5/5, 5/10, 10/10 mg. The assessment of treatment was done in 2 months follow-up.
Results. During treatment there was significant decrease of office systolic and diastolic blood pressure (BP). Target BP was reached in 82,6% cases. The mean daily values of systolic and diastolic BP load became lower. During the treatment, there was improvement of clinical condition by functional class of CHF. The score by CAS decreased from 6,2+1,1 to 4,2+1,3 (р<0,01) and exercise tolerance increased: six-minute walking test distance from 160,4+14,5 to 307,14+13,1 m (р<0,01). Also, the level of cystatin C decreased in plasma, and GFR increased, witnessing the improvement of functional capacity of kidneys as a result of treatment.
Conclusion. The fixed combination of perindopril arginine and amlodipine besilate can be successfully applied into treatment of AH and CHF patients with the signs of CKD.
About the Authors
N. Yu Borovkova
Nizhny Novgorod State Medical Academy of the Ministry of Health
Russian Federation
Russian Federation
Т. Е. Kuznetsova
Fespharm Company, filial of Fespharm NN
Russian Federation
Russian Federation
N. N. Borovkov
Nizhny Novgorod State Medical Academy of the Ministry of Health
Russian Federation
Russian Federation
A. A. Tulichev
Nizhny Novgorod State Medical Academy of the Ministry of Health
Russian Federation
Russian Federation
A. S. Ilyina
Nizhny Novgorod State Medical Academy of the Ministry of Health
Russian Federation
Russian Federation
References
1. Lazebnyk LB, Postnikov SL. Chronic heart failure in the elderly. Breast cancer 2015; 21: 34-8. Russian (Лазебник Л. Б. Постникова С. Л. Хроническая сердечная недостаточность у пожилых. РМЖ 2015; 21: 34-8).
2. Napalkov DA, Sulimov VA, Seidov NM. Chronic heart failure: shifting the focus to the initial stage of the disease. Journal Attending Vrach 2015; 8(4): 23-5. Russian (Напалков Д. А., Сулимов В. А., Сеидов Н. М. Хроническая сердечная недостаточность: смещение фокуса на начальные стадии заболевания. Журнал Лечащий врач 2015; 8(4): 23-5).
3. Mareev VY Ageev FT, Arutyunov GP, et al. National guidelines GFCF and PRAs for the diagnosis and treatment of chronic heart failure (fourth revision). Journal of Cardiac Insufficiency 2013; 14(81): 379-472. Russian (Мареев В. Ю., Агеев Ф. Т., Арутюнов Г.П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность 2013; 14(81): 379-472).
4. Conradi AO. Key achievements in the combined antihypertensive therapy in recent years. Magazine Hypertension 2012; 18(6): 3-12. Russian (Конради А. О. Ключевые достижения в комбинированной антигипертензивной терапии последних лет. Журнал Артериальная гипертензия" 2012; 18 (6): 3-12).
5. Moiseev VS, Mukhin NA, Smirnov AV, et al. Cardiovascular risk and chronic kidney disease: strategy of cardionephroprotection. National guidelines. Clinical Pharmacology 2014; 23 (3): 4-27. Russian (Моисеев В. С., Мухин Н. А., Смирнов А. В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Национальные рекомендации. Клиническая фармакология 2014; 23 (3): 4-27).
6. Serov VA, Shutov A.M, Makeeva ER, et al. Chronic kidney disease and the prognosis of patients with chronic heart failure. Cardiology PFD: Opportunities and Prospects:
7. Sat. Proceedings of the III Congress of Cardiology of the Volga Federal District. Samara, 2010. p.250. Russian (Серов В. А., Шутов А. М., Макеева Е. Р. и др. Хроническая болезнь почек и прогноз больных с хронической сердечной недостаточностью. Кардиология ПФО: возможности и перспективы: сб. материалов III съезда кардиологов Приволжского федерального округа. Самара, 2010. С. 250).
8. Smirnov AV, Shilov EM, Dobronravov EA, et al. Chronic kidney disease: the basic principles of screening, diagnosis, prevention and treatment approaches. (National guidelines). SPb.: Publisher Lefty; 2012. Russian (Смирнов А.В, Шилов Е. М., Добронравов Е. А. и др. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. (Национальные рекомендации). СПб.: Издательство Левша; 2012).
9. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Suppl 2012; V 2, Issue 1: 1-126.
10. Nebieridze DV, Safaryan AS, Kamyshova TV. Topical issues of the combination therapy of hypertension. Heart: a magazine for practicing physicians 2012; 11(3): 171-4. Russian (Небиеридзе Д. В., Сафарян А. С., Камышова Т. В. Актуальные вопросы комбинированной терапии артериальной гипертензии. Сердце: журнал для практикующих врачей 2012; 11(3): 171-4).
11. Dahlof B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10-16; 366: 895-906.
Review
For citations:
Borovkova N.Yu., Kuznetsova Т.Е., Borovkov N.N., Tulichev A.A., Ilyina A.S. SELECTION OF THE OPTIMAL ANTIHYPERTENSION TREATMENT IN PATIENTS WITH CHRONIC HEART FAILURE WITH THE SIGNS OF CHRONIC KIDNEY DISEASE. Cardiovascular Therapy and Prevention. 2016;15(6):19-23. (In Russ.) https://doi.org/10.15829/1728-8800-2016-6-19-23
Views:
1225
Email this article 
